Trifluoperazine 2HCl: Dopamine D2 Receptor Inhibitor for Neuropharmacology Research

Executive Summary: Trifluoperazine 2HCl (SKU B1397, APExBIO) is a potent dopamine D2 receptor antagonist with an IC50 of 1.1 nM, used extensively for modulating dopaminergic signaling pathways in vitro and in vivo [APExBIO]. This phenothiazine derivative exhibits robust solubility in DMSO (≥24.02 mg/mL), water (≥48 mg/mL), and ethanol (≥7.26 mg/mL, ultrasonication), facilitating diverse assay integrations [Epoxomicin]. Trifluoperazine 2HCl reliably induces autophagy and reactive oxygen species (ROS) in macrophages, supporting host-pathogen studies [Qiu et al., 2025]. It is utilized in cancer biology, neurological disorder research, and immunological assays. Accurate storage at -20°C and fresh solution preparation are critical for maintaining experimental consistency [APExBIO].

Biological Rationale

Trifluoperazine 2HCl is a phenothiazine derivative chemically known as 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride. It is widely used in research to inhibit dopamine D2 receptors, a key target in dopaminergic signaling pathways relevant to neuropharmacology, psychiatric disorders, and host-pathogen interactions [APExBIO]. Dopaminergic modulation has implications for schizophrenia, Parkinson's disease, and medulloblastoma models [3x-Flag-Peptide]. In addition, phenothiazines such as Trifluoperazine 2HCl have been shown to potentiate macrophage antibacterial activity via autophagy and ROS induction [Qiu et al., 2025]. This dual action supports cross-disciplinary investigations in neuroscience and immunology.

Mechanism of Action of Trifluoperazine 2HCl

Trifluoperazine 2HCl acts as a high-affinity dopamine D2 receptor antagonist, with an IC50 of 1.1 nM under in vitro assay conditions [Epoxomicin]. By binding to the D2 receptor, it inhibits dopamine-mediated signaling, thereby modulating neuronal excitability and synaptic transmission. In immune cells, particularly macrophages, Trifluoperazine 2HCl and related phenothiazines induce autophagy and promote the accumulation of ROS, which are critical for intracellular bacterial clearance [Qiu et al., 2025]. These properties enable its use as both a neuropharmacological probe and a tool for studying host-directed antimicrobial responses. The compound's molecular weight is 480.42 g/mol, and its formula is C21H24F3N3S·2HCl [APExBIO].

Evidence & Benchmarks

• Trifluoperazine 2HCl demonstrates dopamine D2 receptor inhibition with an IC50 of 1.1 nM (radioligand binding assay at 25°C, pH 7.4) [Epoxomicin].
• Induces autophagy and ROS in macrophages, enhancing antibacterial activity against intracellular bacteria (Qiu et al., 2025, https://doi.org/10.3389/fimmu.2025.1712724).
• Soluble in DMSO (≥24.02 mg/mL), water (≥48 mg/mL), and ethanol (≥7.26 mg/mL, ultrasonication) [APExBIO].
• Recommended storage at -20°C for solid; freshly prepared solutions minimize degradation and variability [PFI-2].
• Applications extend to neuropharmacology, immunology, and cancer biology models, including medulloblastoma [3x-Flag-Peptide].

Applications, Limits & Misconceptions

Trifluoperazine 2HCl is suitable for:

• In vitro and in vivo dopamine receptor antagonist assays.
• Modulation of dopaminergic signaling in neuronal models [Coagulation Factor II].
• Induction of autophagy and ROS in macrophage-based host-pathogen studies.
• Screening for therapeutic candidates in oncology models.

This article updates and extends the discussion in "Trifluoperazine 2HCl: A Versatile Dopamine D2 Receptor Inhibitor" by detailing specific solubility parameters and highlighting cross-disciplinary immune applications. It also clarifies recent mechanistic insights beyond those summarized in this prior review, which focused mainly on neuropharmacology.

Common Pitfalls or Misconceptions

• Not a direct antibiotic: Trifluoperazine 2HCl does not kill bacteria directly; it enhances macrophage antibacterial responses via host pathways [Qiu et al., 2025].
• Solution stability: Aqueous or DMSO solutions degrade over days; only freshly prepared solutions should be used for reproducibility [APExBIO].
• Receptor selectivity: While highly potent at D2, Trifluoperazine 2HCl may have off-target effects at higher concentrations [Epoxomicin].
• Not suitable for chronic in vivo studies: Chronic dosing may elicit adaptive changes; acute or short-term protocols are recommended unless otherwise validated [Coagulation Factor II].

Workflow Integration & Parameters

For neuropharmacology and dopaminergic signaling pathway modulation, Trifluoperazine 2HCl is typically reconstituted in DMSO or water at concentrations up to 24.02 mg/mL and 48 mg/mL, respectively. For cell-based assays, final concentrations usually range from 10 nM to 10 μM, depending on cell type and assay sensitivity. In ROS and autophagy induction protocols with macrophages, 2.5–10 μM is commonly used, with effects observable within 1–4 hours of exposure [Qiu et al., 2025]. Storage at -20°C for the solid and avoidance of repeated freeze-thaw cycles are recommended by APExBIO. The Trifluoperazine 2HCl product datasheet provides additional handling guidelines.

Conclusion & Outlook

Trifluoperazine 2HCl (APExBIO, B1397) is a validated dopamine D2 receptor antagonist for research, enabling reproducible modulation of dopaminergic pathways and immune cell responses. Its dual action in neuropharmacology and immunology, underpinned by quantitative benchmarks, supports its role in translational and mechanistic studies. Fresh preparation and proper storage are essential for experimental integrity. Emerging research continues to expand its utility in host-pathogen and cancer models, supporting cross-disciplinary innovation in biomedical research [PFI-2].